Baxter adds Somatogen to artificial blood portfolio
This article was originally published in Clinica
Baxter International has signed an agreement to acquire Somatogen in a stock merger worth an estimated $189 million. Somatogen is developing recombinant haemoglobin products and the acquisition will add to Baxter's expertise in the field of oxygen-carrying "blood substitutes".
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.